Peptide profile
Published Data as of
PepBank's records hold no result from a study in people for TB-500.1 They hold 22 findings in animals and 14 laboratory findings, as of October 30, 2026.1 A trial registry lists 1 trial of TB-500 in people.1 In rats with repaired Achilles tendons, TB-500 increased maximum load to failure compared with controls.2 PepBank's regulatory record lists TB-500 as not approved for any use.3
In horses, researchers gave TB-500 as N-acetylated LKKTETQ.6 TB-500 is one of the peptides in PepBank.1 PepBank's regulatory record lists TB-500 as not approved for any use, as of October 30, 2026.3
PepBank's records hold no result from a study in people for TB-500. A trial registry lists 1 trial of TB-500 in people.1
PepBank holds 22 findings in animals from 6 publications, and 14 laboratory findings in cells or tissue from 4 publications.1 It holds no findings predicted by a computer model.1 The studies of TB-500 in PepBank hold 36 results from 7 studies that gave the peptide.1
In a study in horses, researchers gave TB-500 under the skin to two thoroughbred geldings. They then detected N-acetylated LKKTETQ and its metabolite N-acetylated LK in the plasma of the horses.7 In horses, a test method confirmed N-acetylated LKKTETQ and its metabolites in both urine and plasma.6
In rats treated with TB-500, Ac-LK was the main metabolite and had the highest levels in the first hours.5 In rats, the study called Ac-LKK a long-term metabolite. It was detected up to 72 hours.5
In 5xFAD mice, TB-500 and another peptide, Ac-SDKP, improved performance in the Morris water maze and in novel object recognition.4 In 5xFAD mice, the two peptides markedly reduced glial activation and neuronal apoptosis on immunohistochemistry.4
In 5xFAD mice, the peptides restored axonal density in the perirhinal cortex and attenuated plaque-associated dystrophic neurites.4 In 5xFAD mice, they did not change hippocampal beta-amyloid (Aβ) burden.4
In a laboratory study in nerve cells treated with an Aβ fragment, TB-500 and Ac-SDKP restored cell viability and reduced neurite atrophy.4 In microglia cells, the peptides suppressed nitric oxide production after lipopolysaccharide treatment. In these cells, they also reduced expression of pro-inflammatory cytokines.4
In rats with repaired Achilles tendons, TB-500 increased maximum load to failure compared with controls.2 In rats, TB-500 also lowered both the Bonar and the Movin histopathology scores compared with controls.2 In rats, collagen type III expression differed significantly among groups, but the study did not state the direction for TB-500.2
In rats, Sirius red birefringence showed more organized type I collagen in treatment groups, particularly with TB-500.2 In rats, collagen type I expression did not differ significantly among groups.2 In rats, giving BPC-157 and TB-500 together gave no additional benefit over either agent alone.2
In animals with an alkali burn of the cornea, a TB-500 peptide hydrogel significantly sped epithelial regeneration and reduced inflammation.8 In animals, the hydrogel also improved corneal barrier function.8
In a laboratory study in human corneal stromal fibroblasts, the hydrogel increased myofibroblastic differentiation and cytoskeletal reorganization.8 In human corneal epithelial cells, it promoted tight junction recovery.8
The TB-500 findings in PepBank come from studies in horses, in rats, in mice and in cells.1,4,5,7 PepBank holds 0 publications with findings in people for TB-500, and no findings predicted by a computer model.1
A trial registry lists 1 trial of TB-500 in people, as of October 30, 2026.1 PepBank's records hold no result from a study in people for TB-500 yet.1
PepBank's regulatory record lists TB-500 as not approved for any use, in all places the record covers, as of October 30, 2026.3 PepBank's records hold 0 findings in people for TB-500.1 A trial registry lists 1 trial of TB-500 in people, and PepBank's records show no published result from it yet.1
In horses given a single dose of TB-500, a test method confirmed N-acetylated LKKTETQ and its metabolites in urine and plasma.6 In a study in horses given TB-500 under the skin, its metabolite N-acetylated LK was found in plasma.7 In rats, Ac-LK was the main early metabolite and Ac-LKK was detected up to 72 hours.5
In fibroblast cells, parent TB-500 showed no significant wound healing activity compared with control. Only its metabolite Ac-LKKTE did.5 In fibroblasts in a laboratory study, TB-500 and its metabolites showed no cytotoxicity.5 In human corneal cells, a TB-500 hydrogel promoted cell migration and proliferation.8
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated